Abstracts tagged "Antiphospholipid Antibodies and myocardial involvement"

Abstract Number: 855 • 2018 ACR/ARHP Annual Meeting
IgG Antiphospholipid Antibodies, -a Common but Neglected Finding in Patients with Myocardial Infarction
Giorgia Grosso¹, Natalie Sippl², Barbro Kjellström³, Khaled Amara², Ulf de Faire⁴, Kerstin Elvin⁵, Bertil Lindahl⁶, Per Näsman⁷, Lars Ryden⁸, Anna Norrhammar^9,10 and Elisabet Svenungsson¹¹, ¹Unit of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet, Karolinska University Hospital, Cardiology Unit, Department of Medicine Solna, Stockholm, Sweden, ⁴Division of Cardiovascular Epidemiology IMM, Karolinska Institutet, Stockholm, Sweden, ⁵Dept. of Clinical Immunology and Transfusion Medicine, Unit of Clinical Immunology, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁶Department Medical Sciences, Uppsala University, Uppsala, Sweden, ⁷Center for Safety Research, KTH Royal Institute of Technology, Stockholm, Sweden, ⁸Cardiology Unit, Department of Medicine Solna,, Karolinska Institutet, Stockholm, Sweden, ⁹Cardiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁰Capio S:t Görans hospital, Stockholm, Sweden, ¹¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: The antiphospholipid syndrome (APS) is present when arterial, venous or microvascular thrombosis or obstetric morbidity concur with confirmed positive tests for antiphospholipid antibodies (aPL).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].